Cargando…

A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell-surface proteins on target cells

Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy against refractory B-cell malignancies shows excellent therapeutic effects. However, there are some obstacles to be overcome in this treatment. Since current CAR-T cells target a single cell-surface protein on tumor cells, the CAR-T cells also...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aoyama, Satoru, Yasuda, Shunichiro, Li, Huixin, Watanabe, Daisuke, Umezawa, Yoshihiro, Okada, Keigo, Nogami, Ayako, Miura, Osamu, Kawamata, Norihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846940/ https://www.ncbi.nlm.nih.gov/pubmed/35119085 http://dx.doi.org/10.3892/ijmm.2022.5097

Ejemplares similares

FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM
por: Watanabe, Daisuke, et al.
Publicado: (2019)

Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD–Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway()
por: Nogami, Ayako, et al.
Publicado: (2018)

FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway
por: Okada, Keigo, et al.
Publicado: (2017)

Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells
por: Akiyama, Hiroki, et al.
Publicado: (2020)

Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2
por: Ishida, Shinya, et al.
Publicado: (2018)

FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia
por: Nogami, Ayako, et al.
Publicado: (2015)

Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells
por: Umezawa, Yoshihiro, et al.
Publicado: (2016)

Proliferation and Survival Signaling from Both Jak2-V617F and Lyn Involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 Cell Line Newly Established from Acute Myeloid Leukemia Transformed from Polycythemia Vera
por: Nagao, Toshikage, et al.
Publicado: (2014)

The Effects of Chimeric Antigen Receptor (CAR) Hinge Domain Post-Translational Modifications on CAR-T Cell Activity
por: Hirobe, Sachiko, et al.
Publicado: (2022)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)

Humanized Chimeric Antigen Receptor (CAR) T cells
por: Kozani, Pouya Safarzadeh, et al.
Publicado: (2021)

Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis
por: Tanaka, Keisuke, et al.
Publicado: (2023)

Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma
por: Motomura, Yotaro, et al.
Publicado: (2022)

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2019)

Interspecies Chimeric Barriers for Generating Exogenic Organs and Cells for Transplantation
por: Strell, Phoebe, et al.
Publicado: (2022)

Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
por: Rad S. M., Ali Hosseini, et al.
Publicado: (2021)

Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Aparicio, Cristina, et al.
Publicado: (2021)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
por: De Bousser, Elien, et al.
Publicado: (2021)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
por: Watanabe, Keisuke, et al.
Publicado: (2018)

Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy
por: Kravets, Victoria G, et al.
Publicado: (2017)

Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
por: Sridhar, Praveen, et al.
Publicado: (2017)

Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
por: Sutherland, Ashley R., et al.
Publicado: (2020)

Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)
por: Brown, Kevin, et al.
Publicado: (2021)

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy
por: Staudt, Ross E, et al.
Publicado: (2022)

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review
por: Miao, Lele, et al.
Publicado: (2022)

CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
por: Taneja, Alankrita, et al.
Publicado: (2021)

Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
por: Gajra, Ajeet, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation
por: Gille, Ilse, et al.
Publicado: (2022)

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
por: Sabbah, Mohamad, et al.
Publicado: (2022)

Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy
por: Choi, Gyeyoung, et al.
Publicado: (2022)

Non-viral chimeric antigen receptor (CAR) T cells going viral
por: Balke-Want, H., et al.
Publicado: (2023)

Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
por: Yoon, Dok Hyun, et al.
Publicado: (2018)

Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
por: Salmikangas, Paula, et al.
Publicado: (2018)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

Chimeric antigen receptor (CAR)+ T cell selection method affects transgene efficacy
por: Rushworth, David, et al.
Publicado: (2013)

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
por: Xia, An-Liang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m52glfkg18ajqu3pf0cg9lubms